94 results about "Oncology drug" patented technology

An application of the Japanese butterbur's extract (bakkenolide D, B, IVa and IIIa) in preparing the medicines for preventing and treating liver cancer, lung cancer, cervical cancer, intestinal cancer, kidney cancer, bread cancer, etc is disclosed.

This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate when present as a single phosphate diastereoisomer and, in particular, it relates to the (S)-phosphate diastereoisomer which offers a remarkable and unexpected increase in solubility relative to the (R)-diastereoisomer. The (S)-phosphate epimer is also preferentially taken up into cyclodextrin solutions over the (R)-diastereoisomer.

The invention discloses application of a sugar-containing platinum complex in the preparation of medicines for preventing and treating tumor. The sugar-containing platinum complex is shown as the formula (I). The test proves that the sugar-containing platinum complex shown as the formula (I) can prevent and treat cancer of mammals, such as lung cancer, colon cancer, head and neck cancer, prostatic cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoma, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, stomach cancer, male genital organ cancer, bone cancer and the like of the mammals, in particular can prevent and treat lung cancer, colon cancer, head and neck cancer, prostatic cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoma, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, stomach cancer, male genital organ cancer or bone cancer of human beings.

The invention relates to a new application of sodium-potassium ATP enzyme inhibitor uabain for reversing tolerance of cells of non-small cell lung cancer (NSCLC) to targeted anti-tumor drugs. Particularly, the uabain can be used as a sensitizer for treating the NSCLC and is combined with TRAIL to be used for treating the NSCLC.

The invention relates to indole alkaloid formalardeemin shown in a chemical structural formula ((-)-5-N-formalardeemin), pharmaceutically acceptable salts of the same, and application of the indole alkaloid formalardeemin serving as an anti-tumor medicament in curing malignant tumors of human beings. The indole alkaloid formalardeemin serving as an anti-tumor medicament can not only inhibit the growth of malignant tumors directly, but also can be used as a chemosensitizer when used together with other anti-tumor medicaments such as doxorubicine, vincristine and the like to achieve the effect of effectively killing tumor cells by reversing the multi-drug resistance of the tumor cells. More significantly, compared with the indole alkaloid formalardeemin serving as a tumor cell growth inhibitor directly, the indole alkaloid formalardeemin serving as the chemosensitizer has a better effect, so the indole alkaloid formalardeemin has important clinical application prospect.

The invention discloses an application of combined utilization of triptolide cisplatin in preparation of a pancreatic cancer drug against drug resistance. Experiments on two drug-resistant pancreatic cancer cells PANC-1 and MIAPaCa-2 and nude mice with inoculated with PANC-1 cells on flanks prove that the effects of synergistic tumor inhibition can be achieved for drug-resistant pancreatic cancer through the combined utilization of triptolide cisplatin. So far, no study on the synergistic inhibition of the pancreatic cancer through the combined utilization of triptolide cisplatin is reported. In the nude mouse xenografting model, the tumor growth can be significantly inhibited through the combined utilization of low doses of triptolide and cisplatin, and cannot be inhibited when only the triptolide or cisplatin is used. The results of immunohistochemistry for each group of tumor biopsies show that the HSP27 protein expression can be reduced significantly through the combined utilization of the two drugs, and the results are identical to the results on cell lines. Therefore, the triptolide and cisplatin can be used together as a sensitizing agent of anticancer drugs.

The invention relates to disubstituted phenyl biguanide compounds and application containing the same to inducing malignant tumor cell for anoikis and inhibiting tumor growth and transfer. Proved by in vitro-in vivo experiments, the disubstituted phenyl biguanide compounds show the remarkable functions of inducing the malignant tumor cell for anoikis, starting caspase cascade and inhibiting tumor growth and transfer and also have the characteristics of high efficiency and low toxicity, so the disubstituted phenyl biguanide compounds as pharmaceutical compounds are expected to be applied to a plurality of malignant tumor medicaments for inhibiting the tumor growth, invasion and metastasis and treating human melanoma, neurospongioma, lung cancer, gastric cancer, prostate cancer, ovarian cancer and the like.

The present invention is the application of acetyl boswellic acid (BC-4) extracted from Boswellia carterii Birdw as antitumor medicine, a secondary application. It is found that BC-4 has the functions of resisting the proliferation of tumor cell, inducing malignant tumor cell to death, inhibiting the proliferation of human umbilical vein endothelial cell, inhibiting animal's grafted tumor, inhibiting metastasis of malignant tumor, etc. Both in vivo and vitro tests show that BC-4 has very low toxicity and is one excellent antitumor medicine and tumor metastasis inhibitor.

The invention discloses application of EphrinA1 in tumor development, metastasis, treatment and prognosis of patients. The invention discloses that EphrinA1 is involved in the process of tumor growth,invasion and metastasis. The high expression of EphrinA1 in a gastric cancer tissue leads to poor prognosis of gastric cancer patients, and targeted knockdown or knockout of EphrinA1 expression can significantly inhibit the invasion ability of gastric cancer cells and the metastasis ability of the gastric cancer cells in mice. The invention utilizes a function that an antibody targeting EphrinA1blocks EphrinA1, and can effectively inhibit the invasion ability of the gastric cancer cells. The invention finds that EphrinA1 has an important application value in tumor therapy and can be used asa target for antitumor drugs.

The invention relates to application of degalactotigonin and a derivative thereof in preparation of an antitumor medicine. The nightshade Solanum Linn is extracted and separated from the compound. A pharmacological experiment proves that the degalactotigonin has high inhibition rate on tumor cells at a certain concentration; the anti-patent activity of degalactotigonin is obviously higher than that of a positive medicine 10-hydroxycamptothecine; the desgalactotigonin has relatively low toxicity on normal cells, and can be used for treating tumor diseases such as liver cancer, lung cancer, gastric cancer, colon cancer, breast cancer, ovarian cancer, oral cancer, esophagus cancer, bile duct cancer and leukemia. The invention further discloses a method for extracting degalactotigonin from plants. The method is simple and feasible, and has a good industrial prospect.

The invention relates to antitumor drugs, in particular to application of hellebores aglucon and derivatives thereof, and one or more of pharmaceutically acceptable salts. Experiments of in vitro cell biology show that the compounds can induce cycle arrest of various tumor cells of liver cancer, lung cancer, prostate glands cancer, leucocythemia and the like, remarkably inhibit the cell proliferation, and can be used for preparing drugs for inhibiting the growth of various tumor cells including the liver cancer.

The invention discloses an application of neohesperidin in the preparation of tumor prevention drugs. Pharmacological experiment researches show that the neohesperidin can significantly reduce the number of spontaneous colorectal cancer lesions in APC min / + mice and significantly change the composition proportion of intestinal microflora in mice without affecting the blood lipid level in mice or affecting the proliferation and the apoptosis of intestinal tumor cells. The neohesperidin has a good prevention and treatment effect on the occurrence of intestinal tumors, and is expected to be developed into new tumor prevention drugs or healthcare products.

The invention discloses an application of bufotalin std. in preparing a medicament for treating lung tumors. Proved by in vitro anti-tumor experiments of the bufotalin std., the concentration of medicaments of the animal lungs is higher than the concentration of effecting medicaments, and the bufotalin std. has stronger activity inhibition effect on human non-small cell lung cancer and other lung tumor cell stains, wherein the IC50 is 15-200ng / ml, and the bufotalin std. has good dose-response relationship. Shown as experimental results, the tumor growth inhibition effect of the bufotalin std. is superior to that of medicaments clinically applied at present, and the bufotalin std. has great development and application prospects.

The invention belongs to the technical field of medical devices, and discloses a medical oncology drug delivery device and method, including a handle, a switch, a connecting rod, a transparent cover plate, a drug injection tube, a medicine mix cavity, a sleeve rod, a spring, a micro-photographic head, a medicine feeding pinhole, a micro motor, a chain, a barrier plate, a flat-head bent rod, a lighting lamp, a liquid level detection module, a wireless communication module, a smartphone, a housing and a tumor prediction module. A liquid level detection module detect that data information of theliquid level in the drug mixing cavity in time, and supply the drug liquid to the drug mixing cavity in time. The algorithm of wireless communication module can obtain better capacity performance, andthe difference between the algorithm and the optimal antenna selection algorithm is not very big, which not only maintains the diversity effect of wireless communication system, but also reduces thecomplexity of system coding. In addition, through the tumor prediction module to establish a tumor prediction model, can be more accurate in tumor prediction, to meet the needs of users.

The present invention relates to anti-gastric cancer drugs, in particular to the application of bufadienolactone compounds in anti-gastric cancer drugs. Diacyl arginine ester, cinobufagin-3-adipyl arginine ester, cinobufagin, deacetylated cinobufagin, cinobufagin-3-suberoyl arginine Esters, bufafolin-3-suberoyl arginine ester, 3-dehydrobufafolin and sea bufotoxin and their pharmaceutically acceptable salt-forming compounds. In vitro cell experiments show that the compound of the present invention can significantly inhibit the growth of gastric cancer cell spheres, and therefore can be used to prepare tumor drugs for treating gastric cancer.

The invention relates to application of chemical drugs in the field of medicine, in particular to application of glycocholic acid in preparation of antitumor drugs. The novel applicable field of glycocholic acid is provided herein; glycocholic acid is applicable to the preparation of antitumor drugs, mainly for breast cancer, ovarian cancer, endometrial carcinoma, lung cancer or their combinations; as an effective active ingredient to antitumor drugs, glycocholic acid has effective treatment quantity of 4T1 (mouse breast cancer cells) under 0.4-1.6 nmol / L, and MCF-7 (human breast cancer cells), NIH OVCAR-3 (human ovarian carcinoma cells), RL95-2 (human endometrial cancer cells), and HCC827 (human non-small cell lung cancer cells) under 16-128 mu mol / L. The application is helpful for the development of novel antitumor drugs.

This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations which comprise a polar aprotic solvent, preferably dimethyl acetamide (DMA). Formulations comprising these solvent provide therapeutically effective treatments of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. The invention also relates to methods of using said formulations and kits comprising said formulations.

The invention discloses an application of Vandetanib to preparation of a targeted EphB4 anti-tumor drug, and belongs to the technical field of medicines. Experiments verify the application of the Vandetanib, and a molecular docking method, an SPR (surface plasmon resonance) method and MST (modulated scatterer technique) experiment results indicate that the Vandetanib can interact with EphB4. EphB4kinase experiments display that the Vandetanib can obviously inhibit EphB4 kinase activity. Proliferation of leukemic cells K562, JLTRG and H9 is remarkably inhibited. Besides, the Vandetanib remarkably inhibits expression of signal molecules p-PI3K p85 / p55 and PI3K p85 at the downstream of the EphB4, and the phosphorylation level of MEK (methyl ethyl ketone) and ERK (extracellular signal-regulated kinase) is reduced. Therefore, the experiment results sufficiently support the application of the Vandetanib to an anti-leukemia drug and the targeted EphB4 anti-tumor drug.

The invention relates to three non-clinical antitumor drugs which are found to have anti-tumor effects and mainly can inhibit the proliferation of lung cancer A549 cells or cervical cancer Hela cells. The technical problem to be solved is that some clinical drugs are screened by using the lung cancer A549 cells and the cervical cancer Hela cells, so as to obtain the non-clinical antitumor drugs with the antitumor effects. Key points of technical schemes for solving the problems are as follows: the lung cancer A549 cells and the cervical cancer Hela cells are processed for 48 hours by using drugs of saturated concentration, and the changes of the morphology and quantity of the cells are observed by a microscope; for drugs with inhibitory actions, survival rate and LDH (Lactate Dehydrogenase) activity detection is further carried out on the cells, and Hoechst33258 is applied to cell apoptosis detection. Main purposes: the non-clinical anticancer drugs for remarkably inhibiting the proliferation of the lung cancer A549 cells or cervical cancer Hela cells are found and are applied to the clinical treatment of patients with lung cancer or cervical cancer.

The present invention discloses a class of deuterated 3-(4,5-substituted amino pyrimidine)phenyl derivatives, and applications thereof, wherein the deuterated 3-(4,5-substituted amino pyrimidine)phenyl derivatives are compounds having a structure represented by a formula (I) or pharmaceutically acceptable salts thereof, and the compounds or the salts thereof can be used for the treatment or prevention of diseases or conditions through epidermal growth factors with mutated forms, can effectively inhibit the growths of a variety of tumor cells, can inhibit other proteases of EGFR and Her family,and can be used for preparing antitumor drugs. The formula (I) is defined in the specification.

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is activeagainst tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together withother anti-neoplastic agents and can possess additive or super-additive effects.

The present invention discloses a novel use of rutin as a PRMT1-PXR-P-gp pathway inhibitor for the preparation of a medicament or food for treating a disease associated with the regulation of the PRMT1-PXR-P-gp pathway. At the cellular level, rutin can significantly inhibit the expression of P-gp in human hepatoma cell line HepG2 by inhibiting the PRMT1-PXR-P-gp pathway, thereby reversing the increase in P-gp expression caused by long-term chemotherapy. The phenomenon of multidrug resistance of tumors increases the sensitivity of tumor cells to chemotherapeutic drugs and improves the therapeutic effect of oncology drugs.

The invention discloses the use of PD-0332991 in the preparation of drugs for preventing and treating drug-resistant tumors. The present invention uses cell biology and molecular biology methods, as well as tests on human gefitinib-resistant nude mouse xenograft tumor models to prove that PD‑0332991 can effectively inhibit the growth of human gefitinib-resistant lung cancer cells and induce apoptosis. Regulates cell cycle-related genes, causes tumor cell cycle arrest, and induces apoptosis. Therefore, PD‑0332991 can be used as an active ingredient to prepare drugs for preventing and treating gefitinib-resistant tumors, as well as foods, health products and cosmetics for preventing and treating drug-resistant tumors.

The invention relates to the technical field of medicines, in particular to application of apatinib to preparing BRAF V600E protein kinase inhibitors and application of the apatinib to preparing medicines for treating BRAF V600E mutation tumor. Melanoma, thyroid papillary carcinoma, borderline ovarian tumor, colorectal cancer, non-small cell lung cancer and hairy cell leukemia can be treated by the medicines. The application has the advantages that novel targets and indication can be provided for the apatinib; novel thinking can be provided for treating tumor such as BRAF V600E mutation melanoma, colorectal cancer and non-small cell lung cancer.

The invention discloses an antitumor drug, namely, a membrane-permeable short peptide / matrine antitumor drug, with a targeting effect on epithelial-sourced malignant tumors. The antitumor drug is prepared from matrine derivative active ester reacting with membrane-permeable short peptides containing seven amino acids under the basic condition. The membrane-permeable short peptide / matrine reserves the anti-cancer effect of matrine and membrane permeability and targeting ability of the short peptides, and can perform the targeting effect on the epithelial-sourced malignant tumors, especially liver cancer. Compared with clinically applied matrine, the membrane-permeable short peptide / matrine has obvious liver cancer cell targeting ability, and can rapidly penetrate through the liver cancer cell membrane, inhibit liver cancer cell proliferation and induce liver cancer cell apoptosis.

The invention provides a glyoxalase I irreversible inhibitor shown as the formula I (pleases see the formula in the description) and a preparation method and application thereof. The glyoxalase I irreversible inhibitor reacts with glyoxalase I in a covalent bond mode to enable the glyoxalase I to be irreversibly inactivated. The glyoxalase I irreversible inhibitor has good application and development prospects on preparation of drugs for treating malignant tumors such as a prostatic cancer, a lung cancer, an intestinal cancer, a bladder cancer, leukemia, a breast cancer and a skin cancer and various relapsed tumors.

This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate when present as a single phosphate diastereoisomer and, in particular, it relates to the (S)-phosphate diastereoisomer which offers a remarkable and unexpected increase in solubility relative to the (R)-diastereoisomer. The (S)-phosphate epimer is also preferentially taken up into cyclodextrin solutions over the (R)-diastereoisomer.